Company
Global pharmaceutical company, known as MSD outside the US/Canada, maker of cancer drug Keytruda and a broad portfolio of vaccines and medicines.
Joint Economic Committee Democrats say Trump's pharma stock reached up to $56.2 million by the end of 2025, from up to $1.7 million in 2024. Up to $39.1 million of it is in drugmakers that benefited from Medicare negotiation exemptions, and the White House denies any conflict.
Reality
Merck and Moderna are preparing to file their personalized mRNA melanoma vaccine after a Phase 3 trial showed it delayed recurrence. At the STAT Summit, executives said the next task is showing it works in other tumors, and that they must pick where to look first.
Reality
Vaxcyte said its 31-strain pneumococcal vaccine hit its primary Phase 3 endpoints in a trial against Pfizer's 20-strain and Merck's 21-strain shots. The trial compared antibody levels, so the strain-by-strain results will decide how far the extra coverage threatens the two incumbents.
Perspective Coverage
3 publishersReality
Merck and Moderna's mRNA vaccine intismeran autogene slowed the return and spread of melanoma when added to an existing treatment in a late-stage trial. One trial cannot say which other cancers the same approach can treat.
Reality
Intismeran autogene plus Keytruda beat Keytruda alone in resected melanoma. The market added roughly $35bn to Moderna on a result the companies described only in adjectives.
Perspective Coverage
6 publishersReality
Intismeran autogene met both primary endpoints in a 1,137-patient melanoma trial. Every dose is built from one tumour's sequence, which turns approval into a question about process, not product.
Perspective Coverage
3 publishersReality
The companies say intismeran plus Keytruda slowed melanoma's return after surgery in the first randomized Phase 3 test of neoantigen vaccines. No detailed data has been released.
Perspective Coverage
4 publishersReality
Kiwoom's S&P 500 Momentum ETF replaced 54 of its 99 holdings in one scheduled rebalance, putting Apple on top at 9.23%, dropping Nvidia and Broadcom, and raising Intel and AMD to 4.89% each.
Reality
Hana Asset Management's medical AI fund led every ETF listed in South Korea last week, helped by a Morgan Stanley estimate that Medicare coverage could add $330m to $400m of annual revenue at its largest holding.
Reality
The Aug. 10 order also cuts the routine childhood list from 18 vaccines to 11 on the argument that the United States is out of step with Europe, and the pediatricians who have read it say no new safety or efficacy data came with it.
Reality
Revolution Medicines' daraxonrasib nearly doubled median overall survival in previously treated patients. Investors sat still anyway, because the unresolved variable is now what payers will absorb.
Reality
Intismeran autogene would arrive with a selection procedure where other drugs have a fixed molecule, and the outside expert STAT asked could not say what the software weighs. That makes the ranking code the hard part of any review.
Reality
Eight investors are named on the round and no valuation was disclosed. The only outside corroboration of Faro's data model covers how it writes protocols, not what agents do with them.
Reality
MassBio's annual snapshot pairs a recovering VC, IPO and M&A market with a 39% fall in seed capital, a 6% drop in NIH awards and 3,605 lost jobs.
Reality
Stanford's April 2026 tests put debate ahead of rival multi-agent designs, and behind a solo agent at matched compute. The comparison a framework vendor quotes is the first one.
Reality
The global Ervebo stockpile released doses for an outbreak the shot was not licensed against. Most of them will be given outside the trial that could tell anyone whether it works.
Reality
Moderna shares rose more than 100% after the melanoma Phase 3 hit, and a co-founder's net worth went from $730 million to $1.7 billion. The wealth number is a risk gauge, not a story.
Reality
ClickHouse has acquired Langfuse, folding the leading open-source LLM observability project into the database it already ran on. Teams that standardized on it inherit a lock-in decision.
Reality
A record long-bond yield in the US and decade-high yields in Germany and France are the week's real story. Mortgages moved first; AI capex plans are next in line for scrutiny.
Reality